SEKISUI XenoTech Announces Enhanced Synergy in ADME Testing Services
Kansas City, KS– SEKISUI XenoTech is collaborating with the Drug Development Solutions Center to offer a full suite of nonclinical testing services specializing in the evaluation of Absorption, Distribution, Metabolism, and Excretion (ADME) in potential new drugs.
For nearly 25 years SEKISUI XenoTech has been highly regarded for its extensive selection of drug metabolism-focused test systems and in vitro services investigating drug metabolism and drug-drug interactions in support of safety and risk mitigation for drug developers. Now with support from the Drug Development Solutions Center of the SEKISUI Medical Group, a wide range of studies is provided to thoroughly evaluate biotransformation and the potential journey of a prospective drug candidate compound when taken by a patient.
Satoshi Ito, Manager of the Business Planning and Development Department of the Drug Development Solutions Division of SEKISUI Medical, said, “Bringing together the 64 years of in vivo studies and radiolabeling expertise with the exceptional in vitro capabilities of XenoTech creates a partnership that can serve drug developers and ultimately patients worldwide in a wider and more robust capacity than ever before.”
Services offered by the Drug Development Solutions Center include in vivo ADME studies, with specialties in Quantitative Whole Body Autoradiography (QWBA), Metabolite Identification, Mass Balance and Tissue Dissection. These studies utilize highly specialized skills and a deep well of knowledge and experience in radioisotope (RI) labeling technology.
“I am excited to offer these in vivo studies that help to complete our large and comprehensive portfolio of ADME services, which help drug developers to efficiently move effective, safe therapeutics through the pipeline to market where patients can benefit,” stated Dr. Darren Warren, COO of SEKISUI XenoTech.
A recent blog post on the SEKISUI XenoTech website gives a more detailed look into the history and development of both companies and their partnership.
About SEKISUI XenoTech
SEKISUI XenoTech, LLC is a global Contract Research Organization with unparalleled ADME/DMPK/Drug-Drug Interactions experience utilized by 98% of top pharma companies and numerous other organizations. For the past 25 years, the company has offered proven drug development expertise in evaluating drug candidates in compliance with regulatory requirement and guidance prior to entrance to market. The company offers a variety of in vitro safety assessment studies for drug candidate evaluation, as well as an extensive selection of products for drug metabolism and pharmacokinetic research. For additional information, please refer to the company’s website at www.xenotech.com or call (913) 438-7450.
About The Drug Development Solutions Center
The Drug Development Solutions Center is the top contract research organization in Japan offering in vitro and in vivo ADME/PK studies to serve drug developers in the path to market. Their expertise spans more than 60 years, having built a reputation for quality and unmatched skill in radiolabeled studies. For clients outside Japan, studies can be organized through SEKISUI XenoTech.